Frazier Life Sciences is an investment manager focused exclusively on companies developing and commercializing novel therapeutics at all stages, from company formation to publics. Frazier Life Sciences was formed in October 2021, started operations January 1, 2022 and is principally owned by Jamie Topper and Patrick Heron. Dr. Topper owns Frazier Life Sciences indirectly through a wholly-owned entity, Topper Family, LLC, and Mr. Heron owns Frazier Life Sciences indirectly through a wholly-owned entity, Galena Holdings, LLC. As of December 31, 2023, Frazier Life Sciences’ regulatory assets under management is $3,560,674,175, all of which is managed on a discretionary basis. Frazier Life Sciences provides discretionary investment management services to U.S. private investment funds which includes Frazier Healthcare VII, L.P. (managed by its general partner, FHM VII, L.P.), Frazier Healthcare VII-A, L.P. (managed by its general partner, FHM VII, L.P.), Frazier Life Sciences VIII, L.P. (managed by its general partner, FHM Life Sciences VIII, L.P.), Frazier Life Sciences IX, L.P. (managed by its general partner, FHMLS IX, L.P.), Frazier Life Sciences X, L.P. (managed by its general partner, FHMLS X, L.P.), Frazier Life Sciences Public Fund, L.P. (managed by its general partner, FHMLSP, L.P.), Frazier Life Sciences XI, L.P. (managed by its general partner, FHMLS XI, L.P.), and Frazier Life Sciences Public Overage Fund, L.P. (managed by its general partner, FHMLSP Overage, L.P. each a “General Partner,” and collectively, together with any future affiliated general partner entities, the “General Partners”) (collectively, the “Frazier Life Sciences Funds”). In providing such advisory services, Frazier Life Sciences utilizes strategies based on evaluating pharmaceutical and biotechnology companies developing and commercializing novel therapeutics at all stages, from company formation to publics globally. In providing its investment advisory services, each fund’s general partner determines when and which investments will be acquired, disposed of, or exchanged on behalf of its fund clients to maintain a portfolio consistent with each client’s objectives. Additionally, Frazier Life Sciences has provided and may in the future provide certain current or prospective investors or other persons (including other sponsors, market participants, finders, consultants and other service providers, portfolio company management or personnel, Frazier Life Sciences’ personnel and/or certain other persons associated with Frazier Life Sciences and/or its affiliates) the opportunity to participate directly in certain portfolio companies by co-investing alongside the Frazier Life Sciences Funds or in co-invest vehicles that will invest in certain portfolio companies alongside a Frazier Life Sciences Fund. Frazier

Life Sciences Public Fund, L.P. (“FLSPF”) and Frazier Life Sciences Public Overage Fund, L.P. (“Overage Fund,” and together with FLSPF, the “Public Funds”) primarily invest in public pharmaceutical and biotechnology companies, but may also invest up to 20% of their investment portfolio in crossover/mezzanine financings of private companies. All other Frazier Life Sciences Funds primarily invest in private pharmaceutical and biotechnology companies with the ability to invest a limited amount of aggregate subscriptions in public pharmaceutical and biotechnology companies. Frazier Life Sciences’ advisory services to the Frazier Life Sciences Funds consist of (i) investigating, identifying and evaluating investment opportunities; (ii) structuring, negotiating and making investments on behalf of the Frazier Life Sciences Funds; (iii) managing and monitoring the performance of such investments; and (iv) exiting such investments on behalf of the Frazier Life Sciences Funds. Frazier Life Sciences’ advisory services to each Frazier Life Sciences Fund are subject to the specific investment objectives and restrictions applicable to such Frazier Life Sciences Fund, as set forth in such Frazier Life Sciences Fund’s limited partnership agreement, confidential private placement memorandum and other governing documents (collectively, the “Governing Documents”). Investors and prospective investors in each Frazier Life Sciences Fund should refer to the Governing Documents of that Frazier Life Sciences Fund for information on the investment objectives and investment restrictions with respect to that Frazier Life Sciences Fund. There can be no assurance that any of the Frazier Life Sciences Funds’ investment objectives will be achieved or that investors will not lose investment capital. One or more of the Frazier Life Sciences Funds or their General Partners have entered and expect in the future to enter into “side letters” or similar agreements with certain investors pursuant to which the Frazier Life Sciences Fund or its General Partner grants the investor specific rights, benefits, or privileges that are not made available to investors generally. Such “side letters” or similar agreements generally are disclosed only to investors in the applicable Frazier Life Sciences Fund that have separately negotiated with Frazier Life Sciences for the right to review such “side letters” or similar agreements. Certain side letter rights are likely to confer benefits on the relevant limited partner at the expense of the relevant Frazier Life Sciences Fund or of limited partners as a whole, including in the event that a side letter confers additional reporting, information rights and/or transfer rights, the costs and expenses of which are expected to be borne by the relevant Frazier Life Sciences Fund.